Karush Justin M, Seder Christopher W, Raman Anish, Chmielewski Gary W, Liptay Michael J, Warren William H, Arndt Andrew T
Department of Cardiovascular and Thoracic Surgery, Rush University Medical Center, 1725W. Harrison St, Suite 774, Chicago, IL, 60612, USA.
Rush Medical College, Chicago, IL, 60612, USA.
Lung. 2017 Oct;195(5):601-606. doi: 10.1007/s00408-017-0023-4. Epub 2017 Jun 16.
The literature is devoid of a comprehensive analysis of silicone airway stenting for benign central airway obstruction (BCAO). With the largest series in the literature to date, we aim to demonstrate the safety profile, pattern of re-intervention, and duration of silicone airway stents.
An institutional database was used to identify patients with BCAO who underwent rigid bronchoscopy with dilation and silicone stent placement between 2002 and 2015 at Rush University Medical Center.
During the study period, 243 stents were utilized in 63 patients with BCAO. Pure tracheal stenosis was encountered in 71% (45/63), pure tracheomalacia in 11% (7/63), and a hybrid of both in 17% (11/63). Median freedom from re-intervention was 104 (IQR 167) days. Most common indications for re-intervention include mucus accumulation (60%; 131/220), migration (28%; 62/220), and intubation (8%; 18/220). The most common diameters of stent placed were 12 mm (94/220) and 14 mm (96/220). The most common lengths utilized were 30 mm (60/220) and 40 mm (77/220). Duration was not effected by stent size when placed for discrete stenosis. However, 14 mm stents outperformed 12 mm when tracheomalacia was present (157 vs. 37 days; p = 0.005). Patients with a hybrid stenosis fared better when longer stents were used (60 mm stents outlasted 40 mm stents 173 vs. 56 days; p = 0.05).
Rigid bronchoscopy with silicone airway stenting is a safe and effective option for the management of benign central airway obstruction. Our results highlight several strategies to improve stent duration.
目前尚无关于硅酮气道支架治疗良性中央气道阻塞(BCAO)的全面分析。基于迄今为止文献中最大的病例系列,我们旨在阐明硅酮气道支架的安全性、再次干预模式及使用时长。
利用机构数据库识别2002年至2015年间在拉什大学医学中心接受硬质支气管镜扩张及硅酮支架置入术的BCAO患者。
在研究期间,63例BCAO患者共使用了243个支架。单纯气管狭窄患者占71%(45/63),单纯气管软化患者占11%(7/63),两者混合型患者占17%(11/63)。再次干预的中位无事件生存期为104(四分位间距167)天。再次干预最常见的指征包括黏液积聚(60%;131/220)、移位(28%;62/220)和插管(8%;18/220)。置入支架最常见的直径为12mm(94/220)和14mm(96/220)。最常用的长度为30mm(60/220)和40mm(77/220)。对于离散性狭窄,支架使用时长不受支架尺寸影响。然而,存在气管软化时,14mm支架的表现优于12mm支架(157天对37天;p = 0.005)。混合型狭窄患者使用较长支架时预后较好(60mm支架比40mm支架的使用时长更长,分别为173天对56天;p = 0.05)。
硬质支气管镜联合硅酮气道支架置入术是治疗良性中央气道阻塞的一种安全有效的选择。我们的结果突出了几种可延长支架使用时长的策略。